Business Description
Zelira Therapeutics Ltd
ISIN : AU000000ZLD1
Total Employee Number:
8Description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | -3.43 | |||||
Debt-to-Equity | -0.48 | |||||
Debt-to-EBITDA | -0.68 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -104.11 | |||||
Beneish M-Score | 13.21 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 42.7 | |||||
3-Year EPS without NRI Growth Rate | 45.7 | |||||
3-Year FCF Growth Rate | 28.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 26.55 | |||||
14-Day RSI | 37.51 | |||||
6-1 Month Momentum % | 20.48 | |||||
12-1 Month Momentum % | 11.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.11 | |||||
Quick Ratio | 0.02 | |||||
Days Inventory | 41407.22 | |||||
Days Sales Outstanding | 26280 | |||||
Days Payable | 147595.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.5 | |||||
Shareholder Yield % | -6.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -800 | |||||
Operating Margin % | -380900 | |||||
Net Margin % | -362800 | |||||
EBITDA Margin % | -317200 | |||||
FCF Margin % | -490700 | |||||
OCF Margin % | -490700 | |||||
ROA % | -122.72 | |||||
ROIC % | -78.96 | |||||
3-Year ROIIC % | -32.13 | |||||
ROC (Joel Greenblatt) % | -1665.97 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -2.4 | |||||
EV-to-EBITDA | -2.6 | |||||
EV-to-Revenue | 8254 | |||||
EV-to-FCF | -1.68 | |||||
Price-to-GF-Value | 4.17 | |||||
Earnings Yield (Greenblatt) % | -41.67 | |||||
FCF Yield % | -82.48 |
Zelira Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zelira Therapeutics Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.005714:1 Stock Split | 2022-04-14 | 3.15 (+0.00%) | ||
| 0.2:1 Stock Split | 2016-10-17 | 4.38 (+0.00%) | ||
| 0.090909:1 Stock Split | 2008-10-02 | 176.47 (+10.00%) | ||
| 0.2:1 Stock Split | 2008-03-06 | 304.81 (+0.00%) | ||
| 1.0158:1 Stock Split | 2004-04-05 | 598.28 (-3.53%) |
Show
Entries
Press Release
Articles on Zelira Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers